Dixit Kalpana, Athawale Rajani B, Singh Sarabjit
C. U. Shah College of Pharmacy, S. N. D. T. Women's University, Sir Vithaldas Vidya Vihar , Mumbai, Maharashtra , India and.
J Microencapsul. 2015;32(2):107-22. doi: 10.3109/02652048.2014.995730. Epub 2015 Jan 5.
Organic solvents are the innate part of pharmaceutical industry, playing vital role in the bulk drug substance as well as finished product manufacturing. Even though they are used for various crucial purposes, they still lack therapeutic beneficial effect and can be toxic if present in unacceptable limits in final product. Hence, their concentration must be regulated in the final pharmaceutical formulation. With the major development in the market of polymeric microparticles in past few decades, drug product manufacturers are paying more attention towards the development of new techniques for reducing residual solvent content of microparticles. This article sheds light on the importance of removal of organic volatile impurities from the formulation and its regulatory aspects. It also highlights how residual solvent affects various physicochemical characteristics of polymeric microparticles and suggests certain solutions as per the current state of art for limiting organic solvent content in the final product.
有机溶剂是制药行业不可或缺的一部分,在原料药以及成品生产中发挥着至关重要的作用。尽管它们用于各种关键目的,但仍然缺乏治疗有益效果,并且如果在最终产品中存在超出可接受限度的量,可能会有毒性。因此,必须在最终药物制剂中对其浓度进行控制。随着过去几十年聚合物微粒市场的重大发展,药品制造商越来越关注开发降低微粒残留溶剂含量的新技术。本文阐述了从制剂中去除有机挥发性杂质的重要性及其监管方面。它还强调了残留溶剂如何影响聚合物微粒的各种物理化学特性,并根据当前的技术水平提出了某些限制最终产品中有机溶剂含量的解决方案。